Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 1/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 1.00 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 9/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 8/20 | 0.54 |
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30697294 | 1.00 | CLK1 (1.00) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4062708 | 0.96 | CLK1 (0.93) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| Acetic Acid SCHEMBL4066978 | 0.95 | CLK1 (0.91) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4795234 | 0.92 | CLK1 (0.85) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4066988 | 0.87 | HTT (1.00) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL14863869 | 0.87 | CLK1 (0.77) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4071064 | 0.85 | HTT (0.81) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4066980 | 0.85 | CLK1 (0.73) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4065608 | 0.85 | HTT (1.00) | CLK1GSK3BDYRK1ACLK4DYRK1B | |
| SCHEMBL4066650 | 0.82 | CLK1 (0.70) | CLK1GSK3BDYRK1ACLK4DYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 800 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3892719-B1 | UNDIFFERENTIATED STATE-MAINTAINING CULTURE MEDIUM FOR PLURIPOTENT STEM CELLS | KANTO KAGAKU (JP) | 2025-02-05 | — | — | EP | claimed |
| EP-4496800-A1 | PEPTIDE TO TREAT ALPHA-SYNUCLEIN AMYLOID BASED DISORDERS | Council of Scientific & Industrial Research (IN) | 2025-01-29 | — | — | EP | claimed |
| US-20240317713-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2024-09-26 | — | — | US | claimed |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | DBCC RES LLC (US) | 2024-09-26 | — | — | US | claimed |
| CN-113166723-B | Undifferentiated maintenance medium for pluripotent stem cells | 关东化学株式会社 | 2024-08-30 | — | — | CN | claimed |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2024-04-23 | — | — | US | claimed |
| CN-117165524-A | Culture system and method for large-scale in-vitro amplification of cord blood-derived hematopoietic stem cells | 山西医科大学 | 2023-12-05 | — | — | CN | claimed |
| WO-2023181070-A1 | PEPTIDE TO TREAT α-SYNUCLEIN AMYLOID BASED DISORDERS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-09-28 | — | — | WO | claimed |
| CN-108295250-B | Oral tumor vaccine and application thereof | 湖北盛齐安生物科技股份有限公司 | 2023-07-21 | — | — | CN | claimed |
| US-20230070582-A1 | UTILIZATION OF FGF ACTIVATORS IN CULTURE MEDIA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-03-09 | — | — | US | claimed |
| WO-2023020566-A1 | BENZO NITROGEN-CONTAINING HETEROAROMATIC RING DERIVATIVE AND USE THEREOF IN MEDICINE | 四川海思科制药有限公司 | 2023-02-23 | — | — | WO | claimed |
| US-20230049767-A1 | EXPRESSION VECTOR PRODUCTION AND HIGH-THROUGHPUT CELL SCREENING | KYMAB LTD (GB) | 2023-02-16 | — | — | US | claimed |
| CN-112831462-B | Compositions, media and methods for inducing reprogramming of human cells to induced pluripotent stem cells | 复旦大学 | 2022-10-18 | — | — | CN | claimed |
| CN-115181164-A | Derivatives of amatoxins and their coupling to cell binding molecules | 杭州多禧生物科技有限公司 | 2022-10-14 | — | — | CN | claimed |
| CN-114794088-B | Human pluripotent stem cell cryopreservation liquid and application thereof | 北京细胞治疗集团有限公司 | 2022-09-27 | — | — | CN | claimed |
| CN-115052970-A | Use of fibroblast growth factor activator in culture medium | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 2022-09-13 | — | — | CN | claimed |
| CN-114794088-A | Human pluripotent stem cell cryopreservation liquid and application thereof | 北京细胞治疗集团有限公司 | 2022-07-29 | — | — | CN | claimed |
| WO-2022149615-A1 | CULTURE MEDIUM FOR EXPANSION CULTURE OF NEPHRON PROGENITOR CELL, METHOD FOR PERFORMING EXPANSION CULTURE OF NEPHRON PROGENITOR CELL, AND METHOD FOR PRODUCING KIDNEY ORGANOID | 国立大学法人京都大学 | 2022-07-14 | — | — | WO | claimed |
| US-12641625-B2 | Method and device for configuring resource selection window for SL group transmission in NR V2X | LG ELECTRONICS INC. (KR) | 2026-05-26 | — | — | US | disclosed |
| US-20050153941-A1 | Increasing Stage Specific Embryonic Antigen (SSEA) and Nanog gene levels; culturing a stem cell using a low molecular weight derivative of 2-(phenylazo)-2-(3,4-dihydro-2H-isoquinoline-1-ylidene) or N-phenylindole | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2005-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD2, DRD1, HTR1D | CLK1 637/4885GSK3B 101/4885DYRK1A 1717/4885 |
| US-20240317713-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, HTR1D | CLK1 637/4885GSK3B 101/4885DYRK1A 1717/4885 |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | ECHS1, GLS2, OAT | CLK1 1305/4885GSK3B 2729/4885DYRK1A 4158/4885 |
| US-20050153941-A1 | Increasing Stage Specific Embryonic Antigen (SSEA) and Nanog gene levels; culturing a stem cell using a low molecular weight derivative of 2-(phenylazo)-2-(3,4-dihydro-2H-isoquinoline-1-ylidene) or N-phenylindole | MKI67, ALPG, NES | CLK1 4264/4885GSK3B 3504/4885DYRK1A 2920/4885 |
| US-12641625-B2 | Method and device for configuring resource selection window for SL group transmission in NR V2X | SLIRP, NMUR2, SLFN12 | CLK1 336/4885GSK3B 2874/4885DYRK1A 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.